JAK2 inhibitors and their impact in myeloproliferative neoplasms

Hematology

Volumn 17, Issue SUPPL. 1, 2012, Pages

  Geyer, Holly L ^a   Tibes, Raoul ^a   Mesa, Ruben A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Acute leukemia; Essential thrombocythemia; JAK2 inhibitor; Myelofibrosis; Myeloproliferative neoplasms; Polycythemia vera; Primary myelofibrosis

Indexed keywords

CYT 387; JANUS KINASE 2 INHIBITOR; LESTAURTINIB; PLACEBO; RUXOLITINIB; SB 1518; TG 101348; UNCLASSIFIED DRUG;

AMYLASE BLOOD LEVEL; ANEMIA; ARTICLE; BLOOD TRANSFUSION; DIARRHEA; DIZZINESS; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DYSPNEA; ENZYME INHIBITION; HEMATOLOGIC DISEASE; HEMATOLOGIC MALIGNANCY; HUMAN; IC 50; INTERMETHOD COMPARISON; LEUKOCYTOSIS; LIVER FUNCTION TEST; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; MYELOPROLIFERATIVE NEOPLASM; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PANCREAS FUNCTION TEST; PERIPHERAL EDEMA; PHLEBOTOMY; PNEUMONIA; POLYCYTHEMIA VERA; PRIORITY JOURNAL; QT PROLONGATION; SIDE EFFECT; SPLENOMEGALY; THROMBOCYTOPENIA; THROMBOCYTOSIS; VOMITING;

ANIMALS; BENZAMIDES; BRIDGED COMPOUNDS; CARBAZOLES; HUMANS; JANUS KINASE 2; MYELOPROLIFERATIVE DISORDERS; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIMIDINES; PYRROLIDINES; SULFONAMIDES;

EID: 84859766271     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/102453312X13336169156375     Document Type: Article

References (10)

1. James C, Ugo V, Le Couédic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144-8.
2. Pardanani A, Tefferi A. Targeting myeloproliferative neoplasms with JAK inhibitors. Curr Opin Hematol. 2011;18:105-10.
3. Tefferi A, Lasho TL, Huang J, Finke C, Mesa RA, Li CY, et al. Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia. 2008;22:756-61.
4. Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010;363:1117-27.
5. Harrison CN, Kiladjian J, Al-Ali HK, Gisslinger H, Waltzman RJ, Stalbovskaya V, et al. Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) vs best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) or post-essential thrombocythemiamyelofibrosis (PET-MF). J Clin Oncol. 2011;29:Abstract LBA6501.
6. Verstovsek S, Kiladjian J, Waltzman RJ, Sandor V, Lukawy J, Garrett WM, et al. RESPONSE: a randomized, open label, phase III study of INC424 in polycythemia vera (PV) in patients resistant to or intolerant of hydroxyurea (HU). J Clin Oncol. 2011;29:Abstract TPS203.
7. Pardanani AD, Caramazza D, George G, Lasho TL, Hogan WJ, Litzow MR, et al. Safety and efficacy of CYT387, a JAK-1/2 inhibitor, for the treatment of myelofibrosis. J Clin Oncol. 2011;29:Abstract 6514.
8. Deeg HJ, Odenike O, Scott BL, Estrov Z, Cortes JE, Thomas DA, et al. Phase II study of SB1518, an orally available novel JAK2 inhibitor in patients with myelofibrosis. J Clin Oncol. 2011;29:Abstract 6515.
9. Pardanani A, Gotlib JR, Jamieson C, Cortes JE, Talpaz M, Stone RM, et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol. 2011;29:789-96.
10. Santos FP, Kantarjian HM, Jain N, Manshouri T, Thomas DA, Garcia-Manero G, et al. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood. 2010;115:1131-6.